REFERENCES
1. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020; 215:108427.
2. Zheng Y, Sun LJ, Xu M, Pan J, Zhang YT, Fang XL, Fang Q, Cai HL. Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China. J Zhejiang Univ Sci B.2020;21(5):378-387.
3. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin. 2020; 3:1-6.
4. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, Su X, Cao B. SARS-CoV-2 and viral sepsis: observations and hypotheses. The Lancet. 2020; 395(10235):1517-1520.
5. Delgado-Roche L, Mesta F. Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection. Arch Med Res. 2020;51(5):384-387.
6. Dolmatova EV, Wang K, Mandavilli R, Griendling KK. The effects of sepsis on endothelium and clinical implications. Cardiovascular Research. 2020; 26:cvaa070.
7. Merad M and Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nature Reviews Immunology . 2020; 20: 355–362.
8. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. 2020; 395(10234):1417-1418.
9. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Is COVID-19 an endothelial disease? Clinical and basic evidence. 2020;Preprints , 2020040204.
10. Chiappelli F, Khakshooy A, Greenberg G. CoViD-19 Immunopathology and Immunotherapy. Bioinformation. 2020;16(3):219-222.
11. Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, Poiani GJ, Amorosa L, Brunetti L, Kong AN. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep . 2020; 11:1-15.
12. Weber D, Davies MJ, Grune T. Determination of protein carbonyls in plasma, cell extracts, tissue homogenates, isolated proteins: Focus on sample preparation and derivatization conditions. Redox Biol.2015; 5:367-380.
13. Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, Blecher-Gonen R, Cohen M, Medaglia C, Li H, Deczkowska A, Zhang S, Schwikowski B, Zhang Z, Amit I. Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. Cell. 2020; 181(7):1475-1488.e12.
14. Perrone LA, Belser JA, Wadford DA, Katz JM, Tumpey TM. Inducible nitric oxide contributes to viral pathogenesis following highly pathogenic influenza virus infection in mice. J. Infect. Dis.2013; 207:1576–1584.
15. Wang JZ, Zhang RY and Bai J. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients. Int J Cardiol. 2020 Aug 1; 312: 137–138.
16. Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, Zhang Z, Qin Y, Li X, Zhao D, et al., Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. National Science Review , 2020; 7(6):1003–1011.
17. Derouiche S. Oxidative Stress Associated with SARS-Cov-2 (COVID-19) Increases the Severity of the Lung Disease - A Systematic Review.J Infect Dis Epidemiol. 2020; 6:121
18. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, Daßler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M, Looney MR, McAllister F, Rayes R, Renaud S, Rousseau S, Salvatore S, Schwartz RE, Spicer JD4, Yost CC, Weber A, Zuo Y, Egeblad M. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020; 217(6): 20200652.
19. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M, Salomé B, Esai Selvan M, Spindler MP, Tan J, van der Heide V, Gregory JK, Alexandropoulos K, Bhardwaj N, Brown BD, et al., and Sinai Immunology Review Project. Immunology of COVID-19: Current State of the Science. Immunity. 2020;52(6):910-941.
20. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, Dai T, Zhang T, Lai Y, Wang J, Liu Z, He A, O’Dwyer M, Hu J. COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome. medRxiv . 2020. 20042655.
21. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020; 215:108448.
22. Dutta A, Das A, Kondziella D, and Stachowiak MK. Bioenergy Crisis in Coronavirus Diseases? Brain Sci . 2020; 10:277.
23. Salimi S, and Hamlyn JM. COVID-19 and Crosstalk with the Hallmarks of Aging. J Gerontol A Biol Sci Med Sci , 2020, Vol. XX, No. XX, 1–8.
24. Taghizadeh-Hesarya F and Akbaria H. The powerful immune system against powerful COVID-19: A hypothesis. Medical Hypotheses . 2020; 140:109762.
25. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated Type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe . 2016;19(2):181–93.
26. Qianwen Zhao, Meng Meng, Rahul Kumar, Yinlian Wu, Jiaofeng Huang, Yunlei Deng, Zhiyuan Weng, and Li Yanga. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int J Infect Dis. 2020; 96: 131–135.
27. Zini G, Bellesi S, Ramundo F, & d’Onofrio G. Morphological anomalies of circulating blood cells in COVID-19. American Journal of Hematology. 2020. doi:10.1002/ajh.25824
28. Terry LNR, Mediaceja VO, Noa LMV, Sánchez FP. (2016). Valor semiológico del frotis de sangre periférica en el estudio de las enfermedades virales. Revista latinoamericana de patología clínica y medicina de laboratorio. Disponible en: https://www.medigraphic.com/pdfs/patol/pt-2016/pt163h.pdf
29. Zheng M, Gao Y, Wang G. et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020; 17, 533–535.
30. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Zhang Y. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. The Journal of Infectious Diseases. 2020; doi:10.1093/infdis/jiaa150.
31. Singh A, Sood N, Narang V, & Goyal A. Morphology of COVID-19-affected cells in peripheral blood film. BMJ case reports. 2020; 13(5): e236117.
32. Wang J, Jiang M, Chen X, & Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: Review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts. Journal of Leukocyte Biology. 2020 doi:10.1002/jlb.3covr0520-272r